The main research focus of the Brueggemann group is Streptococcus pneumoniae (the ‘pneumococcus’), a bacterium that is a major cause of diseases such as pneumonia and meningitis worldwide. Current research involves using high-throughput genotyping and whole genome sequencing techniques and unique collections of isolates to understand pneumococcal evolution, especially evolutionary changes related to antimicrobial and vaccine selective pressures. Molecular epidemiology and population biology provide the foundation for all aspects of the group’s research.
Our work has particular relevance to: i) understanding how antimicrobial resistance determinants evolve and spread; ii) long-term effectiveness of the existing pneumococcal conjugate vaccines; iii) the design of future vaccines; and iv) the development of novel antimicrobials.
Our work takes place at the University of Oxford: https://www.ndph.ox.ac.uk/team/angela-brueggemann
et al., 2021, Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data, The Lancet Digital Health, Vol:3, ISSN:2589-7500, Pages:e360-e370
et al., 2021, Molecular diagnostic assays for the detection of common bacterial meningitis pathogens: a narrative review, Ebiomedicine, Vol:65, ISSN:2352-3964
et al., 2020, The global meningitis genome partnership., Journal of Infection, Vol:4, ISSN:0163-4453, Pages:510-520
et al., 2020, State-of-the-art in the pneumococcal field: Proceedings of the 11(th) International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11), Pneumonia, Vol:12, ISSN:2200-6133, Pages:1-14
et al., 2019, Prophages and satellite prophages are widespread in Streptococcus and may play a role in pneumococcal pathogenesis, Nature Communications, Vol:10, ISSN:2041-1723